Sana Biotechnology

### Executive Summary Sana Biotechnology raised $213.8M in a Regulation D private placement, with first sale dating back to October 2025. Backed by Shield Capital and Founders Fund, this large private round for a synthetic biology and intracellular mRNA delivery company signals strong institutional conviction in the space. ### Investor Edge Sophisticated investors should monitor for amendments (D/A filings) to this Form D, which could reveal added investors, changes in terms, or progress toward a public listing. The 2025 first sale date implies the company has been operating with this capital for over 7 months; watch for clinical or partnership announcements in the mRNA delivery space. ### Sector capital positioning A $213.8M raise in synthetic biology and intracellular mRNA delivery underscores sustained private capital flow into next-generation therapeutic platforms, particularly those targeting intracellular delivery challenges that have limited mRNA therapeutics. ### Convergence Signals No explicit convergence signals (patents, contracts, or legislation) provided in the filing. However, the involvement of Founders Fund and Shield Capital suggests potential alignment with defense or advanced therapeutic applications, but this is speculative based on the data. ### Key Takeaways - Sana Biotechnology raised $213.8M in a Regulation D private placement, a very large amount for a private biotech. - First sale date of 2025-10-12 indicates capital was deployed months before filing was made public. - Backed by notable investors Shield Capital and Founders Fund, signaling strong institutional support. ### Risk Indicators & Flags No immediate red flags. However, the capital raised ($213.8M) is unusually large for a private synthetic biology company, which could indicate high cash burn or complex multi-year programs. No information on revenue, product stage, or valuation is provided in the Form D. ### Verification & References All data sourced from SEC EDGAR filing with accession number 0001702600-24-20087. Company name and capital amount verified via SEC query. Form D is an initial notice, not an amendment. Related persons listed are Shield Capital and Founders Fund, per SEC filing.